The latest update to the NICE guideline (NG28) has seen a paradigm shift in the treatment of type 2 diabetes (T2D) and how it is managed; with the updated guideline recognising cardiovascular risk management as equally important as blood glucose control. It is important to now consider how to implement the updated NICE guideline in clinical practice. This ~7-minute video will provide: Practical guidance on how to implement the new guidelines with your T2D patients in Primary care Tips and advice on how to engage with your T2D patient when discussing the importance of cardiovascular risk management with them.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
